Industry: Pharmaceuticals, Biotechnology
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington’s disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., has demonstrated that it is safe and well tolerated with 25 of 26 patients showing visual acuity stabilization and 23% of those patients experiencing clinically significant improvement in visual acuity eight weeks after a single ( www.sirna.com )
Sirna Therapeutics , Inc.
2950 Wilderness Place
Boulder, Colorado 80301
USA
Tel: (303) 449-6500
Fax: (303) 449-8829